OUR PRODUCTS

Futerpenol® — Natural Metabolic Conditioning for Fish Health, Performance & Bioresilience

A 100 % natural, non-pharmacological system developed by MNL Group to enhance fish immunity, reduce antibiotic dependence, and promote sustainable performance across aquaculture production cycles.

. Animal Health Division

From Nature to Aquaculture Innovation

Futerpenol® is a metabolic conditioning system designed to help fish maintain physiological balance under chronic production challenges such as temperature shifts, transfer, crowding, oxygen variation, and pathogen pressure.

By acting on the metabolic–inflammatory–oxidative axis, Futerpenol® supports better energy allocation, reduced physiological cost, and greater bioresilience throughout the production cycle.

Science, sustainability, and performance — working together to support bioresilient aquaculture.

piscinas-salmon

Product Line

Futerpenol-2-1

Futerpenol® Feed Green
Contributes to metabolic stability, reduced physiological load, and consistent biological performance during key productive stages.

 

FW-XT-1

FWXT®
Supports early metabolic adjustment and redox balance during freshwater and transfer phases (includes Maqui fraction).



FuterCoho-2-1

FuterCoho®
Provides targeted metabolic support for Coho salmon, helping maintain organ function and robustness under fluctuating conditions (includes Maqui fraction).

Logo-futermaqui

FutermaquiXT®
Supports metabolic adjustment and redox balance during all production cicle (includes Maqui fraction).



Scientific Validation

These results are part of a multi-year collaboration with leading research institutions in Chile:

  • Pathovet — histopathological and immune marker analyses.

  • Aquabench — large-scale production data.

  • Universidad Austral de Chile (UACH) 

  • Universidad Católica de Valparaíso (PUCV) 

RESULTS MAY VARY DEPENDING ON SPECIES, PRODUCTION CONDITIONS, AND PROGRAM DESIGN.
Indicators of Metabolic Stability (2017–2023)
Indicator Result Interpretation
CD8+ cells +75% Reflects more stable physiological status under chronic production challenges.
IL-12 +50% Indicates a more balanced metabolic–inflammatory axis.
Total mortality −44% (90 days) Shows increased resilience and recovery capacity.
SRS mortality during use −60% Associated with improved biological stability during long-term challenges.
SRS mortality at cycle close −15% Reflects sustained metabolic consistency.
Antibiotic use −50% Linked to more stable overall performance.
Intestinal damage −25% Indicates better nutrient absorption and energy efficiency.
Growth rate / FCR +15% Suggests improved resource utilization and productivity.

Real-world performance measured across 36 commercial salmon centers (~900,000 fish).

Sustainability & Quality

+ 100 % natural, non-pharmacological formulations.
+ Free from antibiotics, pesticides, heavy metals, dioxins, and furans.
+ Manufactured in Chile under GMP standards.
+ Independently verified by Multianálisis SpA.
+ Continuous local supply and traceable production batches.

 

Reliable quality for a more sustainable industry.

2017–2023

Proven Results in Real Aquaculture Conditions

Over six years of field evaluations across 36 commercial salmon centers (~900,000 fish) demonstrate how Futerpenol™ strengthens fish immunity, reduces mortality, and promotes sustainable aquaculture performance.

These results come from independent assessments by Aquabench, Pathovet, and Chilean universities (UACH and PUCV), validating the consistent impact of our natural immunomodulatory technology.

Proven Results Futerpenol

  • +75% increase in CD8⁺ cytotoxic lymphocytes and +50% higher IL-12 cytokine expression show that Futerpenol™ activates both innate and adaptive immunity.
    This translates into stronger resistance against bacterial and environmental stress, especially during critical production phases like transfer and smoltification.

    Verified by Pathovet, 2017–2022.

  • During 90 days of continuous use, farms reported a 44% reduction in total mortality, reflecting improved fish survival and recovery under commercial farming stress.

    Historical average from 36 centers, validated by Pathovet and UACH.

  • Futerpenol™ users achieved up to 60% lower SRS mortality during active use, and 15% less mortality at cycle closure.
    This outcome is directly linked to immune stimulation and lower bacterial load, reducing the need for reactive antibiotic treatments.

    Source: Aquabench, 2022.

  • Cycle-closed evaluations revealed a 50% reduction in antibiotic use, contributing to antibiotic stewardship and environmental sustainability.
    This aligns with global goals to reduce antimicrobial resistance (AMR) in aquaculture.

    Source: Aquabench, 2022.

  • Histological analyses show 25% less intestinal damage in fish fed with Futerpenol™, improving nutrient absorption and feed conversion ratio (+15% performance gain).
    Better gut integrity not only improves growth but also enhances disease resilience and welfare.

    Source: Pathovet, 2021.

CONTACT US

Partner with the Leaders in Maqui Berry Science

Discover how our standardized Maqui extracts can elevate your formulations with clinically validated antioxidant power.
MNL-products